Stock Watch: Johnson & Johnson’s Q2 Helps Pharma Sentiment

After The Post-Pandemic Sell-Off, Investors Could Be Returning To The Sector

 
• By Andy Smith
  
Generate a summary of this article
Listen to this article
Beta

Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

In the year to the start of second-quarter earnings season, the broad US S&P 500 stock index had risen by nearly 19%. This was partly driven by big technology companies and partly by multiple expansion resulting from investors’ hopes that falling inflation will increase company profits. A notable absentee from this party was the pharmaceutical sector, with the NYSE Arca Pharmaceutical Index (DRG) falling by nearly 2%, while healthcare conglomerate Johnson & Johnson’s (J&J’s) stock price lagged both these indexes with a fall by nearly 10% over the same period.

However, J&J’s second-quarter earnings announcement prompted a greater than 6% stock price rise against the DRG’s rise of just over...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

Article Without An Author Listed

Here is a short description.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Stock Watch: When Development Goes Too Far

 
• By Andy Smith

R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.

Stock Watch: Bad Deals Backfire On Bayer And CSL

 
• By Andy Smith

As the pharma earnings season wrapped up, it seemed like a contest to see which company's stock price dropped the most after their announcement and which made the poorest acquisition.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.